Galantamine improves behavioural disturbances in outpatients with mild to moderate Alzheimer's disease

Background: Data on cholinesterase inhibitor therapy of patients with mild to moderate Alzheimer's disease (AD) that are suffering from behavioural disturbances are limited. The REMINDER non-interventional study (GAL-ALZ-4014) included the assessment of the effectiveness of galantamine and nootropics on behavioural disturbances and cognition in a set of outpatients with mild to moderate AD under everyday practice conditions. Methods: During this 12-month, open-label, non-interventional, German, multicenter study patients (>50 years;) were treated either with galantamine or with nootropics, such as piracetame or…